Anaptys discontinues ulcerative colitis trial after rosnilimab fails endpoints

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. NDAQ
9. TSCO
10. BE

Go back to Anaptys discontinues ulcerative colitis trial after rosnilimab fails endpoints

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

November 10, 2025 9:00 AM EST

Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy at Week 12 does not support further development of rosnilimab in UC and trial will be discontinued, resulting in at least $10 million in savingsWill provide update in H1 2026 on advancement of rosnilimab in RA, which would be funded by strategic or other sources of capital without diluting our royaltiesReiterating commitment to... More